- News & Events
We are a publicly traded, emerging pharmaceutical company (NASDAQ: ADHD) primarily focused on the development and commercialization of novel treatments for CNS and cognitive disorders such as ADHD and Fragile X syndrome.
Alcobra, an Israeli corporation, relentlessly pursues creative, unbeaten paths for the identification, development and commercialization of therapeutics for impairing CNS disorders. We are committed to becoming a leading global player in the pharmaceutical industry through disruptive efficiency and innovation.
Our objective is to develop and commercialize novel, proprietary pharmaceutical products for treatment of central nervous system disorders, particularly cognitive dysfunctions.